|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 05, 2015 ) This report provides comprehensive information on the current therapeutic developmental pipeline of Enceladus Pharmaceuticals BVs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
View Full Report with TOC @ http://www.acutemarketreports.com/report/enceladus-pharmaceuticals-bv-product-pipeline-review-2015
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope:
The report provides brief overview of Enceladus Pharmaceuticals BV including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Enceladus Pharmaceuticals BVs human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
Request a sample of Report @ http://www.acutemarketreports.com/request-free-sample/36766
List of Figures:
Enceladus Pharmaceuticals BV - Pipeline by Top 10 Indication, 2015 6
Enceladus Pharmaceuticals BV - Pipeline by Stage of Development, 2015 7
Enceladus Pharmaceuticals BV - Monotherapy Products in Pipeline, 2015 8
Enceladus Pharmaceuticals BV - Pipeline by Top 10 Molecule Type, 2015 19
Enceladus Pharmaceuticals BV - Pipeline Products by Top 10 Mechanism of Action, 2015 20...
List of Tables:
Enceladus Pharmaceuticals BV, Key Information 4
Enceladus Pharmaceuticals BV, Key Facts 4
Enceladus Pharmaceuticals BV - Pipeline by Indication, 2015 6
Enceladus Pharmaceuticals BV - Pipeline by Stage of Development, 2015 7
View all reports of this category @ http://www.acutemarketreports.com/category/pharmaceutical-market
Enceladus Pharmaceuticals BV - Monotherapy Products in Pipeline, 2015 8
Enceladus Pharmaceuticals BV - Phase II, 2015 9
Enceladus Pharmaceuticals BV - Phase I, 2015 10...
About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Contact info:
Chris Paul
Office No 01, 1st Floor,
Aditi Mall, Baner, Pune,
MH, 411045 India
Phone (India): +91 7755981103
Toll Free (US/Canada): +1-855-455-8662
Email: sales@acutemarketreports.com
Web: www.acutemarketreports.com
Acute Market Reports
Chris Paul
+917755981103
sales@acutemarketreports.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
